Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Announcement on Voluntary Disclosure of Initiation of Phase 3 Clinical Trial of GR1802 for Indications for Allergic Rhinitis Treatment

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Initiation of Phase 3 Clinical Trial of GR1802 for Indications for Allergic Rhinitis Treatment

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis